Preview complete
The prescreener preview is complete. You may now close the preview.
T-Cell Response to Vaccination
Recruiting
50-100 years
All
Phase
N/A
1 Location
Brief description of study
The purpose of this study is to see
how your body forms a protective response after vaccination and how it deals
with viral variants. We are studying the immune response to the COVID-19
vaccines.
Detailed description of study
The study consists of a screening
visit followed by other study visits. From the time of screening, you will be
in this study for around 9 months.
You
may be eligible if you plan to receive the vaccine (initial or booster) but
have not yet gotten it yet.
The COVID-19 vaccination study includes: a screening visit
(approx 1 hour) to check your eligibility. If you qualify, you will come in for
the following study visits: Study Visit 1 - Pre-Donor Evaluation (30 min) and
Leukopheresis (approx 2.5-4 hours), Visit 2 – vaccination at your place of
choice. The study team will not be
providing the vaccine. Study Visits 3 - 8 - Blood Draws (approx 30 mins), Study Visit 9
- Leukopheresis (approx 2.5-4 hours).
There are additional optional procedures that you
may choose to participate in. These include fine needle aspiration (FNA) of the
lymph nodes under your armpit to see how protective antibodies are being
generated. You may also choose to participate in periodic blood
draws/leukopheresis to see how immune protection holds up over the long-term.
Compensation is provided after the screening visit if eligible for the study.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: healthy Volunteers,healthy subjects,Healthy,Healthy volunteer,healthy,healthy volunteer,healthy volunteers,healthy subjects,COVID-19,coronavirus,covid,vaccine,vaccination,covid-19,covid-19 vaccinations
-
Age: Between 50 Years - 100 Years
-
Gender: All
Must be receiving a COVID-19 vaccines or booster
Must be willing to consent to blood draws
Updated on
27 Aug 2024.
Study ID: 820884
Pre-Screener
